Abeona Therapeutics Inc vs EPR Properties — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while EPR Properties trades at $60.34 (market cap $4.58B). The key difference: EPR Properties is far larger — about 10.9× Abeona Therapeutics Inc's market cap, and EPR Properties pays a 6.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EPR | |
|---|---|---|
Market Cap | $421.19M | $4.58B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $64.32 |
52-Week Low | $4.17 | $48.71 |
Enterprise Value | $276.10M | $8.09B |
Dividend Yield | — | 6.22% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
EPR Properties trades at $60.32, down 0.13% recently, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 results, beating FFO estimates, and raised full-year guidance. Revenue grew to $699 million in 2026, though net income dipped to $263 million. Analysts maintain a consensus price target of $65.30, with 27% buy ratings, but technical indicators suggest near-term pressure.
The outlook is mixed: fundamental strength from dividend growth and acquisitions supports long-term value, but technical bearishness and elevated valuation ratios pose risks. Investors should weigh the 6% dividend yield against potential volatility from interest rate sensitivity and market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →